FDA grants orphan drug designation to Vivesto's Cantrixil for acute myeloid leukemia

Vivesto AB announced that the U.S. FDA granted orphan drug designation to its Cantrixil for the treatment of acute myeloid leukemia.

Detected & updated continuously · Source: Nebula